ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2022 American Transplant Congress

TOPIC: Clinical Science » Kidney » 36 - Kidney Immunosuppression: Desensitization

  • A2/A2B to B Kidney Transplantation Outcomes: A Single-Center 5 Year Experience

    A. El Chediak, S. Shawar, M. Fallahzadeh, I. Feurer, S. Rega, J. L. Triozzi, D. Shaffer

  • Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up

    A. Vo1, J. Tang1, N. Ammerman1, E. Huang1, X. Zhang2, M. Haas3, A. Peng1, R. Najjar1, S. Williamson1, C. Meyers1, S. Sethi1, K. Lim1, M. Gillespie1, N. Badash1, S. Jordan1

  • Desensitization Protocol Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab in Highly Sensitized Kidney Transplant Recipients

    M. Okada, T. Hiramitsu, T. Tomosugi, K. Futamura, S. Narumi, N. Goto, Y. Watarai

  • Desensitization Protocol to Prevent Severe Oliguric Antibody-Mediated Rejection

    H. Ishida1, K. Unagami1, T. Kamzawa1, K. Omoto1, H. Shimizu1, K. Tanabe2

  • Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation

    J. D. Motter1, K. Jackson1, A. Massie1, J. Garonzik-Wang2, D. Segev1

  • Excellent Long-Term Outcome of ABO-Incompatible Living Kidney Transplantation by Reduced-Session of Plasmapheresis of Desensitization Protocol

    Y. Ishiyama1, K. Tanabe2, T. Kanzawa2, K. Unagami2, H. Ishida2, T. Takagi2

  • Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial

    N. Wilson1, S. R. Reese2, L. Ptak3, F. Aziz2, S. Parajuli2, V. Jucaud4, S. Denham4, A. Mishra5, P. Hematti5, A. Djamali2

  • Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests

    M. M. Nasrallah1, M. Elalfy1, Y. Elmesseery2, I. Amer1, P. Malvezzi3, L. Rostaing4

  • Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization

    A. A. Vo1, J. Tang1, S. Williamson1, C. Meyers1, E. Huang1, X. Zhang2, M. Haas3, A. Peng1, R. Najjar1, S. Supreet1, N. Ammerman1, K. Lim1, M. Gillespie1, N. Badash1, S. Jordan1

  • Outcomes of Post-Operative Plasmapheresis in African American Kidney Transplant Recipients with High Panel Reactive Antibodies – A Single Center Experience

    B. Valdepenas, M. Campara, J. Benken, C. Muran, D. Pierce, K. Heagler, P. DiCocco, J. Almario Alvarez, M. Spaggiari, I. Tang, I. Tzvetanov, E. Benedetti

  • 1
  • 2
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences